Entacapone Augmentation for Schizophrenia
Not Applicable
Completed
- Conditions
- Schizophrenia
- Registration Number
- NCT00192855
- Lead Sponsor
- Rambam Health Care Campus
- Brief Summary
This study is testing the hypothesis that Entacapone added to ongoing antipsychotic treatment can be beneficial in schizophrenic patients with negative symptoms.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 52
Inclusion Criteria
- predominantly negative symptoms
- stable on ongoing antipsychotic treatment
Exclusion Criteria
- acute psychotic exacerbation
- suicidal ideation
- uncontrolled systemic disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- FACTORIAL
- Primary Outcome Measures
Name Time Method Improvement in specific rating scales during the study and after completion, compared to baseline. Baseline and once a month untill end of study
- Secondary Outcome Measures
Name Time Method Change in PANSS score. Before and after intervention
Trial Locations
- Locations (1)
Rambam medical center
🇮🇱Haifa, Israel
Rambam medical center🇮🇱Haifa, Israel